辉瑞制药执行副总裁Sally Susman将于2025年底离职,其离职是辉瑞全球重组计划“瘦身”的关键,该计划旨在削减超70亿美元支出以提升组织效率,此举引发业内对药企如何在缩减开支与保持创新间平衡的关注。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.